Vessix veteran becomes JenaValve chairman
This article was originally published in Clinica
Transcatheter aortic valve implantation (TAVI) device contender JenaValve Technology (Wilmington, Delaware and Munich, Germany) has appointed Raymond Cohen chairman. Mr Cohen was CEO of renal denervation specialist Vessix Vascular, a position he held since 2010; Boston Scientific acquired Vessix in a deal worth up to $425 million last year (www.clinica.co.uk, 9 November 2012). He was also chairman and CEO of automatic external defibrillator firm Cardiac Science, between 1997 and 2006. Mr Cohen currently serves on the board of several other firms including BioLife Solutions, which manufactures biopreservation media for human cells and tissues, and LoneStar Heart, a developer of biomaterials for the treatment of congestive heart failure. He replaces previous JenaValve chairman Michael Dormer, who will take up an advisory role.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.